Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...
Abstract: Due to the wide dynamic range in real low-light scenes, there will be large differences in the degree of contrast degradation and detail blurring of captured images, making it difficult for ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the ...
Abstract: In this article, the recursive filtering problem is investigated for a class of discrete-time stochastic dynamical networks where the data delivery from the sensors to the filter is ...
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.90, marking a -4.88% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.51% for ...
Imagine a computer program that doesn’t just do what it’s told, but actively looks at its own code, identifies weaknesses, and rewrites itself to be smarter. Then, with its newly increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results